The future of Ki-67 in this era of precision cancer therapy will depend on accurate and reproducible reporting of Ki-67 immunohistochemistry, only achievable through standardization of pre-analytic, analytic, and post-analytic variables. The gene discussed is MKI67; the disease is cancer.